Daniela I Munteanu, John Dunn, Gábor Apjok, Bálint Kintses, Johann Griselain, Griet Steurs, Christel Cochez, Sarah Djebara, Maya Merabishvili, Jean-Paul Pirnay, Vida Štilec, Matjaž Peterka, Emily A Simpson, Samantha Downie, Alasdair MacInnes, Graeme Nicol, Benedict Clift, Joshua D Jones
{"title":"Phage Therapy for Orthopaedic Infections: The First Three Cases from the United Kingdom.","authors":"Daniela I Munteanu, John Dunn, Gábor Apjok, Bálint Kintses, Johann Griselain, Griet Steurs, Christel Cochez, Sarah Djebara, Maya Merabishvili, Jean-Paul Pirnay, Vida Štilec, Matjaž Peterka, Emily A Simpson, Samantha Downie, Alasdair MacInnes, Graeme Nicol, Benedict Clift, Joshua D Jones","doi":"10.3390/antibiotics14020114","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Bacteriophages (phages) are viruses that infect and kill bacteria. The antimicrobial resistance crisis has driven renewed interest in phage therapy, including the use of phages to treat chronic orthopaedic infections. <b>Methods</b>: Here, we present the results of the first three orthopaedic patients treated with phage therapy in the United Kingdom. <b>Results</b>: The first patient was treated in May 2023 and received phages active against <i>Staphylococcus aureus</i>. At nine months follow-up, the patient's wound remained healed, the C-reactive protein normal and the patient was walking independently. The second patient received phages active against <i>Klebsiella pneumoniae</i> and <i>S. aureus</i>; the infection remained unresolved. The third patient received phages active against <i>Staphylococcus epidermidis</i>; at six months follow-up, the patient was free of infection. Endotoxin was considered at least partially responsible for mild self-limiting adverse effects in two cases. <b>Conclusions</b>: These promising results hint at the potential for phage therapy to transform the care of chronic orthopaedic infections.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"14 2","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11851713/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics14020114","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Bacteriophages (phages) are viruses that infect and kill bacteria. The antimicrobial resistance crisis has driven renewed interest in phage therapy, including the use of phages to treat chronic orthopaedic infections. Methods: Here, we present the results of the first three orthopaedic patients treated with phage therapy in the United Kingdom. Results: The first patient was treated in May 2023 and received phages active against Staphylococcus aureus. At nine months follow-up, the patient's wound remained healed, the C-reactive protein normal and the patient was walking independently. The second patient received phages active against Klebsiella pneumoniae and S. aureus; the infection remained unresolved. The third patient received phages active against Staphylococcus epidermidis; at six months follow-up, the patient was free of infection. Endotoxin was considered at least partially responsible for mild self-limiting adverse effects in two cases. Conclusions: These promising results hint at the potential for phage therapy to transform the care of chronic orthopaedic infections.
Antibiotics-BaselPharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
7.30
自引率
14.60%
发文量
1547
审稿时长
11 weeks
期刊介绍:
Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.